刘湘圣

http://hias.ucas.ac.cn/fzyxy/info/1120/1429.htm

中国科学院杭州医学所特聘研究员，博士生导师，国家优秀青年科学基金项目（海外）获得者。2009和2014年分别获浙江大学学士学位和博士学位。2014年8月赴美国加州大学洛杉矶分校（UCLA）博士后研究工作；2019年6月，升任项目科学家。2020年10月回国加入中国科学院杭州医学所，获国家自然科学基金青年项目、浙江省海外高层次人才创新长期项目和浙江省卫生高层次创新人才项目等资助。累计发表SCI论文70余篇，总引用5000余次，其中第一作者与通讯作者代表性工作发表在Journal of Clinical Investigation (JCI), ACS Nano，Advanced Science, Nature Communications等国际知名学术期刊上。作为核心发明人，申请及获授权中国、美国专利10余项，并开展相应临床转化。

研究方向：主要开展核酸适体靶向药物、mRNA药物与疫苗、智能纳米药物载体、肿瘤免疫治疗、纳米-生物界面效应等研究, 旨在为癌症、重大传染性疾病等提供更加安全、有效的防治手段。

Email: [xsliu@zju.edu.cn](mailto:xsliu@zju.edu.cn)Liu Xiangsheng

http://hias.ucas.ac.cn/fzyxy/info/1120/1429.htm

Positions: Distinguished Researcher of the Hangzhou Institute of Medicine, Chinese Academy of Sciences; Doctoral Advisor; Recipient of the National Excellent Young Scientists Fund Project (Overseas).

Profile:

Educational Background: Received a bachelor's degree and a Ph.D. from Zhejiang University in 2009 and 2014 respectively.

Work Experience:

In August 2014: Began postdoctoral research at the University of California, Los Angeles.

In June 2019: Promoted to a Project Scientist.

In October 2020: Returned to China to join the Hangzhou Institute of Medicine, Chinese Academy of Sciences.

Funded by the Youth Science Fund Project of the National Natural Science Foundation of China, Zhejiang Provincial Program for High-Level Overseas Talents (Long-Term Innovative Talents), and Zhejiang Provincial Program for High-Level Innovative Health Talents.

Publications:

Published over 70 SCI papers with a total of over 5,000 citations.

Published his representative works in prestigious journals such as the Journal of Clinical Investigation, ACS Nano, Advanced Science, and Nature Communications as a first author and corresponding author.

Patents:

Applied for and received over 10 patents in China and the United States as a core inventor.

Engaged in corresponding clinical translation.

Research Directions:

Focusing on nucleic acid aptamer-targeted drugs, mRNA drugs and vaccines, intelligent nano drug carriers, cancer immunotherapy, and nano-bio interface effects.

Aiming to provide safer and more effective prevention and treatment methods for cancer and major infectious diseases.

E-mail: xsliu@zju.edu.cn